ACADIA Pharmaceuticals Inc.

ACADNASDAQHealthcare● Active

$21.70

+$0.14(+0.65%)

Market Cap$3.7B

P/E Ratio—

52W High$28.35

52W Low$19.69

Avg Volume1.8M

Open$21.70

Beta0.83

Overview

ACADIA Pharmaceuticals Inc. (ACAD) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · ACAD · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

ACADIA Pharmaceuticals Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

ACAD insider buying and selling by quarter

ACAD insider selling · ACAD insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

945K473K0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · ACAD ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

ACAD executive sell shares · ACAD board member insider trading · ACAD insider trading SEC filing

Showing 48 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 29, 2026	BAKER BROS. ADVISORS LP Director	Award	18,622	—	—	39,384,587	Form 4
May 29, 2026	BAKER BROS. ADVISORS LP Director	Award	18,622	—	—	3,677,357	Form 4
May 29, 2026	HARRIGAN EDMUND Director	Option	8,107	—	—	43,148	Form 4
May 29, 2026	Ndu Adora Director	Option	8,107	—	—	32,908	Form 4
May 29, 2026	Brege Laura Director	Option	8,107	—	—	23,202	Form 4
May 29, 2026	Poole Jonathan Director	Option	2,010	—	—	2,010	Form 4
May 29, 2026	GAROFALO ELIZABETH A. Director	Option	8,107	—	—	33,489	Form 4
May 29, 2026	Daly James M Director	Option	8,107	—	—	12,148	Form 4
May 26, 2026	Kihara James PRINCIPAL ACCOUNTING OFFICER	Sale	5,401	$21.18	$114K	24,509	Form 4
May 1, 2026	Kihara James PRINCIPAL ACCOUNTING OFFICER	Option	2,596	—	—	30,461	Form 4
May 4, 2026	Kihara James PRINCIPAL ACCOUNTING OFFICER	Sale	1,332	$21.79	$29K	29,129	Form 4
May 1, 2026	Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER	Option	6,815	—	—	69,651	Form 4
May 4, 2026	Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER	Sale	3,506	$21.79	$76K	66,145	Form 4
Apr 5, 2026	Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER	Option	5,276	—	—	65,545	Form 4
Apr 7, 2026	Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER	Sale	2,709	$22.20	$60K	62,836	Form 4
Apr 5, 2026	Kihara James PRINCIPAL ACCOUNTING OFFICER	Option	2,010	—	—	28,895	Form 4
Apr 7, 2026	Kihara James PRINCIPAL ACCOUNTING OFFICER	Sale	1,030	$22.20	$23K	27,865	Form 4
Mar 24, 2026	Owen Adams Catherine CEO · Director	Option	23,509	—	—	26,444	Form 4
Mar 25, 2026	Owen Adams Catherine CEO · Director	Sale	11,641	$21.47	$250K	14,803	Form 4
Mar 24, 2026	Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC	Option	7,515	—	—	15,124	Form 4
Mar 25, 2026	Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC	Sale	3,844	$21.47	$83K	11,280	Form 4
Mar 24, 2026	Thompson Elizabeth H.Z. EVP, Head of Research & Dev	Option	6,715	—	—	6,715	Form 4
Mar 25, 2026	Thompson Elizabeth H.Z. EVP, Head of Research & Dev	Sale	3,435	$21.47	$74K	3,280	Form 4
Mar 25, 2026	Kihara James PRINCIPAL ACCOUNTING OFFICER	Option	2,142	—	—	27,994	Form 4
Mar 26, 2026	Kihara James PRINCIPAL ACCOUNTING OFFICER	Sale	1,097	$21.65	$24K	26,897	Form 4

BAKER BROS. ADVISORS LP

Director

Award

Date

May 29

18,622

Price

—

Value

—

View Form 4 on SEC.gov

BAKER BROS. ADVISORS LP

Director

Award

Date

May 29

18,622

Price

—

Value

—

View Form 4 on SEC.gov

HARRIGAN EDMUND

Director

Option

Date

May 29

8,107

Price

—

Value

—

View Form 4 on SEC.gov

Ndu Adora

Director

Option

Date

May 29

8,107

Price

—

Value

—

View Form 4 on SEC.gov

Brege Laura

Director

Option

Date

May 29

8,107

Price

—

Value

—

View Form 4 on SEC.gov

Poole Jonathan

Director

Option

Date

May 29

2,010

Price

—

Value

—

View Form 4 on SEC.gov

GAROFALO ELIZABETH A.

Director

Option

Date

May 29

8,107

Price

—

Value

—

View Form 4 on SEC.gov

Daly James M

Director

Option

Date

May 29

8,107

Price

—

Value

—

View Form 4 on SEC.gov

Kihara James

PRINCIPAL ACCOUNTING OFFICER

Sale

Date

May 26

5,401

Price

$21.18

Value

$114K

View Form 4 on SEC.gov

Kihara James

PRINCIPAL ACCOUNTING OFFICER

Option

Date

May 1

2,596

Price

—

Value

—

View Form 4 on SEC.gov

Kihara James

PRINCIPAL ACCOUNTING OFFICER

Sale

Date

May 4

1,332

Price

$21.79

Value

$29K

View Form 4 on SEC.gov

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICER

Option

Date

May 1

6,815

Price

—

Value

—

View Form 4 on SEC.gov

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICER

Sale

Date

May 4

3,506

Price

$21.79

Value

$76K

View Form 4 on SEC.gov

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICER

Option

Date

Apr 5

5,276

Price

—

Value

—

View Form 4 on SEC.gov

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICER

Sale

Date

Apr 7

2,709

Price

$22.20

Value

$60K

View Form 4 on SEC.gov

Kihara James

PRINCIPAL ACCOUNTING OFFICER

Option

Date

Apr 5

2,010

Price

—

Value

—

View Form 4 on SEC.gov

Kihara James

PRINCIPAL ACCOUNTING OFFICER

Sale

Date

Apr 7

1,030

Price

$22.20

Value

$23K

View Form 4 on SEC.gov

Owen Adams Catherine

CEO · Director

Option

Date

Mar 24

23,509

Price

—

Value

—

View Form 4 on SEC.gov

Owen Adams Catherine

CEO · Director

Sale

Date

Mar 25

11,641

Price

$21.47

Value

$250K

View Form 4 on SEC.gov

Rhodes Jennifer J

EVP, CHIEF LEGAL OFFICER, SEC

Option

Date

Mar 24

7,515

Price

—

Value

—

View Form 4 on SEC.gov

Rhodes Jennifer J

EVP, CHIEF LEGAL OFFICER, SEC

Sale

Date

Mar 25

3,844

Price

$21.47

Value

$83K

View Form 4 on SEC.gov

Thompson Elizabeth H.Z.

EVP, Head of Research & Dev

Option

Date

Mar 24

6,715

Price

—

Value

—

View Form 4 on SEC.gov

Thompson Elizabeth H.Z.

EVP, Head of Research & Dev

Sale

Date

Mar 25

3,435

Price

$21.47

Value

$74K

View Form 4 on SEC.gov

Kihara James

PRINCIPAL ACCOUNTING OFFICER

Option

Date

Mar 25

2,142

Price

—

Value

—

View Form 4 on SEC.gov

Kihara James

PRINCIPAL ACCOUNTING OFFICER

Sale

Date

Mar 26

1,097

Price

$21.65

Value

$24K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 2

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About ACAD insider trading

ACAD insider trades

ACADIA Pharmaceuticals Inc. (ACAD) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER), Kihara James (PRINCIPAL ACCOUNTING OFFICER), Rhodes Jennifer J (EVP, CHIEF LEGAL OFFICER, SEC). Over the past 12 months, 5 insiders have filed transactions with the SEC. ACAD insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For ACADIA Pharmaceuticals Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

ACAD insider trading · 5 questions

The insiders of ACADIA Pharmaceuticals Inc. (ACAD) include executives and directors such as Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER), Kihara James (PRINCIPAL ACCOUNTING OFFICER), Rhodes Jennifer J (EVP, CHIEF LEGAL OFFICER, SEC), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

ACAD board member insider tradingwho are ACAD insidersACAD insider rosterACADIA Pharmaceuticals Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026